Clinical trial
A Multicenter, Single-arm, Phase II Study to Evaluate a Safety and Efficacy of Obinutuzumab Induction Followed by 2 Years of Maintenance in Patients With Relapsed/Refractory Waldenström Macroglobulinemia.
NCT03679455 is registered in ClinicalTrials.gov with Polish Myeloma Consortium as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Single-arm, Phase II Study to Evaluate a Safety and Efficacy of Obinutuzumab Induction Followed by 2 Years of Maintenance in Patients With Relapsed/Refractory Waldenström Macroglobulinemia.
- Lead sponsor
- Polish Myeloma Consortium
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- September 21, 2018
- Completion date
- December 31, 2022
- Enrollment
- 30 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.